On September 29, 2012, ARIAD Pharmaceuticals, Inc. ("Company") issued a press release announcing the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The study provides compelling clinical evidence of the anti-tumor activity of AP26113 at multiple dose levels in patients with anaplastic lymphoma kinase positive (ALK+) NSCLC and initial clinical evidence of anti-tumor activity in patients with epidermal growth factor receptor mutant (EGFR-m) NSCLC. The results were presented on September 29, 2012 at the ESMO 2012 Congress of the European Society for Medical Oncology held in Vienna, Austria.

A copy of the press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.

(d) The following exhibit is filed with this report:

Exhibit
Number  Description

99.1    Press Release dated September 29, 2012.